Moreover, WNT was the second most enriched LBH-associated pathway in liver, pancreatic, rectal cancer; the third most enriched in esophageal (ESCA) and bladder (BLCA) cancer, and the fourth in prostate cancer (PRAD) (Supplementary Table S5). This evidence concerns the gene LBH and bladder transitional cell carcinoma.